Edition:
United Kingdom

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

125.25USD
8:59pm GMT
Change (% chg)

$0.61 (+0.49%)
Prev Close
$124.64
Open
$126.13
Day's High
$127.90
Day's Low
$123.50
Volume
308,991
Avg. Vol
509,360
52-wk High
$147.63
52-wk Low
$35.98

Select another date:

Mon, Jan 8 2018

BRIEF-Sanofi And Alnylam Pharmaceuticals Enter Into Partnership

* AND ALNYLAM, ANNOUNCED ON SUNDAY STRATEGIC RESTRUCTURING OF RNAI THERAPEUTICS RARE DISEASE ALLIANCE

Sanofi to market new hemophilia drug in deal with Alnylam

PARIS French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals.

Sanofi to market new hemophilia drug in deal with Alnylam

PARIS, Jan 8 French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals.

BRIEF-Alnylam And Sanofi Submit Marketing Authorisation Application (MAA) To The European Medicines Agency (EMA)

* ALNYLAM AND SANOFI SUBMIT MARKETING AUTHORISATION APPLICATION (MAA) TO THE EUROPEAN MEDICINES AGENCY (EMA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS Source text for Eikon: Further company coverage:

BRIEF-‍Sanofi, Alnylam submit marketing authorization application to EMA for Patisiran

* Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis

BRIEF-FDA Lifts Clinical Hold On Fitusiran

* ALNYLAM PHARMACEUTICALS INC - CLINICAL TRIAL DOSING TO RESUME AROUND YEAR-END 2017

FDA allows Alnylam to restart hemophilia treatment trials

The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical trials on a drug to treat patients with a rare bleeding disorder, the company said on Friday.

UPDATE 1-FDA allows Alnylam to restart hemophilia treatment trials

Dec 15 The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical trials on a drug to treat patients with a rare bleeding disorder, the company said on Friday.

FDA allows Alnylam to restart hemophilia treatment trials

Dec 15 The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical tests on a drug to treat patients with a rare bleeding disorder, the company said on Friday.

BRIEF-Alnylam Completes NDA Submission To U.S. FDA For Patisiran For Treatment Of HATTR Amyloidosis

* ALNYLAM COMPLETES SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS Source text for Eikon: Further company coverage:

Select another date: